ANN ARBOR, Mich., June 5 /PRNewswire/ -- Compendia Bioscience today announced that it has signed a two-year licensing agreement with GlaxoSmithKline (NYSE: GSK) for Oncomine(TM) Enterprise Edition, a value-added product extension Compendia's flagship product, Oncomine. Oncomine Enterprise Edition builds upon the features of Oncomine Professional and Concepts editions by integrating the ability to securely view proprietary gene expression data in comparison with existing public data already available in Oncomine.
Oncomine is a rapidly growing compendium of nearly 26,000 gene expression and DNA copy number profiles collected and curated from the literature and other public sources. These data are coupled with analysis functions and a web application for data mining and visualization. Oncomine Concepts Map, licensed to commercial users as part of the Oncomine Enterprise Edition, uses gene sets as a common language to compare and link disparate biological concepts, allowing researchers to discover and explore new biology based on signatures related to drugs and/or disease pathways.
"We are pleased to welcome GlaxoSmithKline to our growing list of major pharmaceutical and biotech customers," said John Freshley, Chief Business Officer of Compendia Bioscience. "GSK has long been a leader in the field of cancer genomics and we look forward to working closely with them to advance their oncology discovery and development efforts."
About Compendia Bioscience, Inc.
Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. The Oncomine Platforms are used by thousands of cancer researchers worldwide in academic institutions as well as biotech and pharmaceutical companies to advance the molecular understanding of cancer and cancer treatment. http://www.compendiabio.com
|SOURCE Compendia Bioscience, Inc.|
Copyright©2008 PR Newswire.
All rights reserved